Palleon Pharmaceuticals

On October 7, our Scientific Co-Founder, Carolyn Bertozzi, will give a lecture at the Nobel Conference at Gustavus Adolphus College titled, “Glycans: The Sugars Coating Our Cells.” As part of this year’s event theme: “Sugar: Bringing Sweetness to Light," Dr. Bertozzi’s talk will focus on a thin layer of sugars that covers the surface of all cells and its role in cancer progression.      Since 1965, the annual conference has served as a forum for leading scientists and thinkers to explore new scientific frontiers. Dr. Bertozzi’s talk will take place nearly three years after she received the Nobel Prize in Chemistry for pioneering click and bioorthogonal chemistry, an approach that enabled the development of our glycan editing therapeutic platform. We’re looking forward to hearing how the field has grown since then and learning about the latest advancements in oncology therapies that target cell-surface sugars.      Learn more about this event and watch online here: https://bit.ly/48adQK4    #NobelPrize #Glycotime #Glycobiology 

On World Cancer Research Day we celebrate the scientific community that is bringing us closer to new cancer treatments, and we recognize the contributions made by our own #glycobiology peers. Glycobiology-based medicines may hold the key to combatting immune suppression caused by the sugars, or glycans, found on cell surfaces which limit the body’s ability to attack cancer. Learn about a group committed to creating solutions for cancer, the Alliance of Glycobiologists for Cancer Research: https://bit.ly/3VewpoI #CancerResearch #WorldCancerResearchDay

The Phase 2 clinical trial of Palleon’s E-602 (HLX79) in combination with Henlius’ rituximab (HANLIKANG) in patients with active glomerulonephritis, including membranous nephropathy (MN) and lupus nephritis (LN), is currently enrolling. This is the first application of Palleon’s glyco-immunology approach in autoimmune disease. E-602 is designed to transform treatment paradigms by enabling the targeting of pathogenic immune cells. Active glomerulonephritis includes autoimmune kidney diseases like MN and LN, where the body’s immune system attacks its own healthy tissues. MN can lead to nephrotic syndrome, a collection of symptoms caused by kidney damage that results in low blood albumin levels, high blood lipids, and significant swelling, and is more common in East Asia and Europe. LN similarly affects the kidney, leading to kidney damage in patients with systemic lupus symptoms. Learn more about this trial, currently enrolling in China: https://bit.ly/3JT1Jad #glomerulonephritis #autoimmunedisease #clinicaltrial

A recent publication in Nature has uncovered a new layer of immune regulation, expanding the fundamental role of glyco-immunology. Moving beyond proteins and lipids, researchers demonstrated that sugar modifications—specifically glycosylation—can shield RNAs from immune detection. This mechanism plays an important role in cell surface RNA function, where it facilitates the non-inflammatory clearance of dead cells. This discovery underscores how glycobiology continues to reshape our understanding of the immune system and how future therapies can harness these signaling pathways to treat #autoimmune diseases and #cancer. Read the paper here: https://lnkd.in/e-zmh2dK #Glycobiology #Immunology #RNA

Palleon’s glyco-immunology approach is an entirely new strategy for treating autoimmune disease that helps deplete dysfunctional immune cells and resets the immune system with healthy cells.   Our lead candidate, E-602, enzymatically degrades cell surface sugar molecules that allow autoreactive memory B cells and pro-fibrotic macrophages to evade detection. When combined with B-cell targeting therapies like rituximab, E-602 may enhance the depletion of antibody-resistant B cells, reduce harmful macrophages, and provide long-lasting relief for patients. Learn more about the power of glyo-immunology and the unique dual-mechanism of E-602 on our updated Science and Approach page: https://bit.ly/3DUGdvt   #Glycoimmunology #AutoimmuneDisease

Palleon’s work spans scientific disciplines and countries. This week, our scientific Co-founder and Nobel laureate Carolyn Bertozzi travelled to Shanghai—the home of our clinical trial partner Henlius. In a keynote address to local students and university faculty members, Dr. Bertozzi highlighted the transformative potential of combining glycobiology with immunotherapy, describing it as a “penicillin moment” for cancer. Palleon and Henlius are advancing the emerging field of glyco-immunology by developing E-688—a therapeutic candidate designed to enhance the immune response by enzymatically degrading immunosuppressive cell-surface sugars on cancer cells. Read more about Dr. Bertozzi’s talk here: https://bit.ly/41NshQj

We’re thrilled to welcome Palleon’s newest clinical advisors: Matthew Baker, M.D., M.S., Paul Brunetta, M.D., and William Robinson, M.D. Bolstering Palleon’s expertise in autoimmunity, they bring decades of experience growing academic and industry programs as well as providing clinical trial leadership that includes the development of an anti-CD20 therapy. Visit our About Us page to explore their full bios and view the complete list of our clinical and scientific advisors: https://bit.ly/3O2kvu1

Our team took a trip to Worcester to see the WooSox in action! We had a ball alongside a few of our honorary, mini teammates who joined us to incorporate some family fun. We cherish moments like these - whether in the lab or at a baseball diamond!

As part of our vision to reach more patients by harnessing the potential of glyco-immunology, we’re excited to announce that the first patient has been dosed in the Phase 2 clinical trial evaluating E-602 (HLX79) in combination with Henlius’ rituximab (HANLIKANG) in patients with active #glomerulonephritis, including membranous nephropathy and lupus nephritis. This is the first application of our approach in autoimmune disease and the most advanced trial of E-602 to date.     We look forward to building on our successful partnership with Henlius to deliver new treatments to patients.    Learn more about the trial in our latest press release: https://lnkd.in/e4ZaGs-d #glycotime #biotech #autoimmunedisease #glycobiology 

Did you know that the Society for Glycobiology’s Annual Meeting is coming up this fall? 🔬 This meeting offers an opportunity to hear leading glycobiologists and emerging scientists from around the world discuss the latest innovations in #glycobiology. This November, learn about the newest breakthroughs in our field – from plant glycobiology to novel experimental drugs which could improve the lives of patients. Register and view the current event schedule here: https://bit.ly/4k7hbff #glycotime